Patent classifications
C07D225/02
METHOD FOR PRODUCING LAUROLACTAM, DEVICE FOR SYNTHESIZING SAME, LAUROLACTAM COMPOSITION PRODUCED THEREBY, AND METHOD FOR PRODUCING POLYLAUROLACTAM USING SAME
Provided are a method of preparing laurolactam including: a) synthesizing laurolactam by Bechmann rearrangement of cyclododecanone oxime under a catalyst system, b) mixing the laurolactam synthesized in a) with a good solvent and removing the catalyst system, and c) mixing the laurolactam from which the catalyst system has been removed in b) with a poor solvent and performing recrystallization, a synthesis device thereof, a laurolactam composition prepared therefrom, and a method of preparing polylaurolactam using the laurolactam composition.
METHOD FOR PRODUCING LAUROLACTAM, DEVICE FOR SYNTHESIZING SAME, LAUROLACTAM COMPOSITION PRODUCED THEREBY, AND METHOD FOR PRODUCING POLYLAUROLACTAM USING SAME
Provided are a method of preparing laurolactam including: a) synthesizing laurolactam by Bechmann rearrangement of cyclododecanone oxime under a catalyst system, b) mixing the laurolactam synthesized in a) with a good solvent and removing the catalyst system, and c) mixing the laurolactam from which the catalyst system has been removed in b) with a poor solvent and performing recrystallization, a synthesis device thereof, a laurolactam composition prepared therefrom, and a method of preparing polylaurolactam using the laurolactam composition.
Quaternary ammonium salt compound, preparation method therefor and use thereof
A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.
Quaternary ammonium salt compound, preparation method therefor and use thereof
A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.
Method for producing optically active substance, optically active substance, method for producing chiral molecule, and chiral molecule
Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.
Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders
AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders. ##STR00001##
Charged ion channel blockers and methods for use
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
Charged ion channel blockers and methods for use
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
Synthesis of N-vinyl compounds by reacting cylic NH-compounds with acetylene in presence of homogenous catalyst
A process can be used to produce N-vinyl compounds by homogeneous catalysis. In the process, acetylene is reacted with a cyclic compound having at least one nitrogen as a ring member, hearing a substitutable hydrogen residue (cyclic compound C), in a liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (RuCat).
Synthesis of N-vinyl compounds by reacting cylic NH-compounds with acetylene in presence of homogenous catalyst
A process can be used to produce N-vinyl compounds by homogeneous catalysis. In the process, acetylene is reacted with a cyclic compound having at least one nitrogen as a ring member, hearing a substitutable hydrogen residue (cyclic compound C), in a liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (RuCat).